Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Allogeneic PBSC Transplant for Older AML Patients in First Remission
NCT00045435Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2002
- Primary completion
- Jan 2009
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of peripheral blood stem cells in acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Disease-free Survival at 1 year and Nonrelapse Mortality at 200 days. Started Apr 2002; status: completed.
02
Drugs
peripheral blood stem cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00045435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045435.